Aims Intra-aortic balloon pumping reduces afterload and may be effective in improving reperfusion in high risk infarct patients treated with primary angioplasty.
Introduction
Primary angioplasty has been shown to be an effective reperfusion strategy for patients with evolving myocardial infarction [1, 2] . Thrombolysis in Myocardial Infarction (TIMI) 3 flow of the infarct-related vessel is achieved in most patients and the reocclusion rate is low compared with patients treated with thrombolytic therapy [3] . However, in a substantial minority of patients, ST-segment elevation persists after primary angioplasty, despite restored flow of the infarct-related epicardial vessel, suggesting impaired myocardial flow [4] . This occurs particularly in patients with large anterior infarctions, and in other high risk patients. Intra-aortic balloon pumping results in afterload reduction and an increase in diastolic coronary flow [5] . Therefore, its use in the setting of acute myocardial infarction might be beneficial. Previous reports showed that intra-aortic balloon pumping after reperfusion therapy prevented reocclusion of the infarct vessel. However, it did not affect left ventricular function, and did not prevent haemodynamic deterioration [6] [7] [8] . We conducted a randomized trial to evaluate the systematic use of intra-aortic balloon pumping in high-risk myocardial infarct patients treated with primary coronary angioplasty.
Methods

Randomization and stratification
All patients who were transferred to the Weezenlanden hospital for treatment with primary or rescue angioplasty were considered for entry into the study. Specific inclusion criteria were: (1) arrival in the hospital within 3 h after start of symptoms, (2) age younger than 70 years, (3) anterior or non-anterior infarct location with cumulative ST-segment deviation of more than 20 mm. Verbal informed consent was obtained from all patients. The trial was approved by the committee on ethics and research at our institute. Patients were randomized prior to angiography and angioplasty and were allocated to either intra-aortic balloon pumping or no intra-aortic balloon pumping. For patients who were allocated to standard treatment but who had signs of cardiogenic shock (pulmonary wedge pressure >18 mmHg, systolic hypotension <90 mmHg and/or mixed venous blood oxygen saturation <65%), crossover to balloon pumping was pre-specified.
Coronary angiography and coronary angioplasty
All patients were treated with 300 mg intravenous acetylsalicylic acid and intravenous nitroglycerine in a dose to maintain a systolic blood pressure of around 110 mmHg. Intravenous heparin was given in a bolus of 10 000 U and thereafter in a continuous infusion in a dosage to keep the activated partial thromboplastin time between two and three times the normal value for at least 2 days. Coronary angiography and angioplasty was performed using standard techniques. Flow through the infarct-related vessel was scored according to the TIMI classification. Coronary angiography and angioplasty procedure data were collected and graded by two of the investigators who were both blinded to the patients' treatment allocation. Consensus on collateral flow, procedural success, TIMI flow before and after the angioplasty procedure, identification of the infarct-related vessel, and extent of coronary artery disease was reached in all cases. TIMI flow before angioplasty was judged at the first injection of the contrast agent.
Definitions
Successful PTCA was defined as a visually assessed <50% residual stenosis and TIMI grade 3 flow. Recurrent myocardial infarction was defined as chest pain, changes in the ST-T segment at rest, and a second increase in the creatine kinase level to more than twice the upper limit of normal, or an increase of more than 200 U per litre over the previous value if the level had not dropped below the upper limit of normal. All patients with a possible or suspected stroke were reviewed by a neurologist and underwent a computed tomography scan. Major bleeding was defined as a need for blood transfusion during hospitalization. Heart failure was defined as Killip class 2 to 4 heart failure.
Reocclusion of the infarct-related vessel was defined as a reduction of TIMI grade 3 flow to TIMI grade 0 or 1 on a follow-up angiogram. Only patients with clinically suspected reocclusion (recurrent chest pain and ST segment elevation), underwent follow-up angiography.
Intra-aortic balloon pumping
The intra-aortic balloon pump (Datascope , Hoevelaken, The Netherlands) was inserted via the femoral route using a 12 French sheath immediately after PTCA. This was effected after a 7 or 8 French sheath had been used for angiography and PTCA. Aortic counterpulsation was continued for 48 h. In cases of limb ischaemia or major haemorrhage at the access site the intra-aortic balloon pump was removed earlier.
Enzymatic infarct size
The methodology for estimation of infarct size has been described previously [9] . In brief, infarct size was estimated by measuring enzyme activity, using lactate dehydrogenase as the reference enzyme. Cumulative enzyme release from five to seven serial measurements up to 72 h after symptom onset (LDHQ 72 ) was calculated. A two-compartment model was used; this has been validated in several studies on the turnover of radiolabelled plasma proteins and circulating enzymes [10] .
Left ventricular function
Left ventricular ejection fraction was measured with a radionuclide technique at the 6 month follow-up. The technique used in our hospital has been described previously [4] . Briefly, it involved the multiple-gated equilibrium method after the labelling of red blood cells with [99mTc] pertechnetate. A gamma camera (General Electric, Milwaukee, U.S.A.) with a low-energy, all purpose, parallel-hole collimator was used. The global ejection fraction is calculated automatically by computer (Star View, General-Electric), with the PAGE program. The data on ejection fractions were gathered by a specialist in nuclear medicine, who was blinded to the clinical data.
Statistical analysis
The primary end-point was defined as the combined incidence of death, reinfarction, stroke or an ejection fraction less than 30% at the 6 month follow-up. The trial was designed to detect a reduction in the primary end-point of 30% to 15%. With 80% power and =0·05 it was estimated that 266 patients were required. Differences between group means were tested by a two-tailed Student t-test. A chi-square method was used to test differences between proportions. The Fisher exact test was used if there was an expected cell value <5. Statistical significance was defined as a P value <0·05. In the presentation of the data, continuous variables are given as mean value SD, whereas discrete variables are given as absolute values and percentages. Analysis was performed on an intention-to-treat basis. A secondary end-point was the weighted unsatisfactory outcome score of different clinical and angiographic end-points, previously described by Braunwald [11] . Each patient is assigned a score that represents the single most serious outcome. This score included death, stroke, heart failure, ejection fraction <30%, reinfarction, reocclusion of the infarct related vessel, or major haemorrhage. Additional secondary end-points were enzymatic infarct size and left ventricular ejection fraction at the 6 month follow-up.
Results
In October 1996, after evaluation of the in-hospital results of 238 included patients, the trial was stopped. Our results, showing no benefit, but potential harm as a result of routine intra-aortic balloon pumping after primary angioplasty, in combination with the results of a similar randomized trial [12] , were decisive in halting the trial. Patient recruitment for the trial is described in Fig. 1 . Between April 1993 and October 1996, 751 patients were candidates for primary angioplasty according to the inclusion criteria of the Zwolle Infarction Trial [1] . Two hundred and seventy-five patients (37%) were transferred from other centres. From these, 37 patients (13%) did not meet inclusion criteria for entry into the intra-aortic balloon pump trial. These patients had non-anterior infarctions and less than 20 mm of cumulative ST segment elevation and were transferred because of contra-indication(s) to thrombolytic therapy. The remaining 238 patients form the basis of this report.
One hundred and eighteen patients were allocated to receive an intra-aortic balloon pump and 120 to standard therapy. The baseline clinical and angiographic characteristics are described in Table 1 and were not different between the two groups, apart from the higher age of the patients in the intra-aortic balloon pump group. Fifty patients (21%) had received previous thrombolytic therapy in the referring hospital. After immediate angiography, 13 patients (5%) were treated conservatively because of non-significant stenosis of the infarct-related vessel and TIMI 3 flow. Ten patients (4%) underwent primary coronary bypass surgery because of significant left main disease or severe triple vessel disease. Crossover occurred in both treatment arms. In the no intra-aortic balloon pump group, 37 patients (31%) did receive an intra-aortic balloon pump. Fourteen patients had severe left main or three-vessel disease, two patients had inadequate reflow after angioplasty, and in 21 patients haemodynamic instability was the reason for crossover. In the group assigned to an intra-aortic balloon pump, 30 patients (25%) did not receive a pump, because of peripheral vessel disease (8), device unavailability (9), patient refusal (2), physician preference (4), or relative contraindications for the device (7).
The primary end-point, the combination of death, recurrent myocardial infarction, stroke or an ejection fraction less than 30% at the 6 month follow-up, was reached in 31 (26%) patients assigned to an intra-aortic balloon pump and in 31 (26%) to no intra-aortic balloon pump (P=0·94) ( Table 2 ). The results of the weighted unsatisfactory outcome score are listed in Table 3 . Patients assigned to a pump had a score of 0·23 (0·36). This was 0·24 (0·36) for patients assigned to no pump (P=0·79). Calculation of LDHQ 72 was performed in 163 (68%) patients and was not significantly different between either group. The left ventricular ejection fraction was measured at discharge in 127 (53%) patients and at the 6 month follow-up in 168 patients (80% of patients alive). No difference in ejection fraction was found in either group of patients ( Table 2) .
Complications of intra-aortic balloon pump
A total of 126 patients were treated with intra-aortic balloon pumping. The mean duration of intra-aortic balloon pumping was 56 h (range 14-216). Serious complications occurred in 10 patients (8%). In four patients, the device had to be removed within 48 h because of limb ischaemia or haemorrhagic complications. Another two patients developed a large groin haematoma after removal of the sheath, for which surgical intervention was necessary. Four patients had symptoms of infection at 52, 96, 126 and 192 h (with positive tip and blood cultures) for which the device was removed. 
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Routine vs elective use of intra-aortic balloon pump
During the study period, 512 patients were not eligible for the study (Fig. 1 ). Of these, 95 patients (21%) underwent intra-aortic balloon pumping because of severe left main or triple-vessel disease, failed reperfusion or cardiogenic shock. Baseline characteristics and outcome are described in Table 4 . Patients who received a pump on indication were older, presented in a higher Killip class, more often had multivessel disease, and repeat revascularization (re-PTCA or CABG) was more often performed during the 6 month follow-up. [9] ; *bleeding during admission requiring transfusion; **combination of death, non-fatal reinfarction, stroke or an ejection fraction <30% at the 6 month follow-up.
Discussion
In this study, frequent use of intra-aortic balloon pumping in high-risk myocardial infarct patients (70% of patients) did not lead to salvage of myocardium or to a better clinical outcome when compared to elective use in 30% of patients. Enzymatic infarct size and left ventricular ejection fraction did not differ between either patient group. Only patients in whom the time between onset of symptoms and arrival in our hospital was less than 3 h were included, because it was hypothesized that insertion of an intra-aortic balloon pump might lead to myocardial salvage in this group of high risk infarct patients who presented early. However, this was not found. A number of other studies have addressed the value of intra-aortic balloon pumping in high risk infarct patients; no improvement in clinical outcome has consistently been found. Most of these studies were non-randomized [5] [6] [7] [8] , however. Two randomized trials have been published. One study in 182 consecutive infarct patients found a higher patency rate of the infarct-related vessel in the intra-aortic balloon pump group at 5-to 10-day follow-up angiography (92% vs 79% TIMI 2/3 flow, P<0·05), together with a significant reduction in the composite clinical end-point of death, stroke, reinfarction, recurrent ischaemia or repeat revascularization [13] . A recent study showed that only thrombolytic treated patients benefit from intra-aortic IABP=intra-aortic balloon pumping; CHF=congestive heart failure; IRV=infarct related vessel; FU=follow-up; *determined by radionuclide technique at the 6 month follow-up. The mean score of intra-aortic balloon pump assigned patients was 0·23 (0·36). The mean score of patients not assigned to intra-aortic balloon pump was 0·24 (0·36), P=0·79. 
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balloon pumping, compared to patients treated with primary angioplasty [14] . As the study of Ohman et al. [13[ mainly included patients who had undergone rescue PTCA for failed thrombolysis, this may be the explanation for the beneficial results for patients allocated to intra-aortic balloon pump therapy in this study. A more recently conducted randomized trial, comprising 437 high risk patients, all treated with primary coronary angioplasty, did not find a reduction in the primary end-point of death, stroke, recurrent infarction, reocclusion or heart failure [15] . The current trial confirmed these results and found no benefit of prophylactic intraaortic balloon pumping after angioplasty for acute myocardial infarction in high risk patients. The primary end-point was not different between patients allocated and not allocated to the device. Moreover, 8% of patients had complications due to the insertion of the intra-aortic balloon pump. This complication rate is lower compared to a report from 1993 from our group, in which serious complications occurred in 16% of 200 consecutive patients treated with intra-aortic balloon pump [16] . However, these patients had different clinical characteristics.
Routine vs elective use of intra-aortic balloon pump
The patients who received an intra-aortic balloon pump after the angioplasty procedure on indication, were of a higher risk category compared to the patients who were part of the randomized trial (Table 4 ) (systematic intraaortic balloon pump use based on clinical high risk criteria): they were older, were in a higher Killip class on admission, less often had a successful angioplasty procedure and had a higher rate of bleeding complications. Despite this, mortality at the 6 month follow-up (13%) was not significantly higher and compares favourably to previous reports in similar patients, with mortality rates of 15% and 40% [8, 14, 17] . This low mortality might be attributed to the intra-aortic balloon pump, which has been shown to be of value in patients with cardiogenic shock [14] , but might also be related to the high rate of repeat revascularization within 6 months. In 49% of intra-aortic balloon pump treated patients (41/83 patients alive) a second revascularization procedure was performed within 6 months, either a re-PTCA because of restenosis or an additional revascularization because of severe triple-vessel disease and inducible ischaemia.
Limitations
The main limitation of the randomized study is the fact that in a substantial minority (25%) of patients assigned to intra-aortic balloon pump therapy, the device was not inserted. This might be related to the fact that randomization was done prior to angiography and therefore the operator was not informed about the coronary and peripheral vessel status of the patient. Also it shows that in clinical practice, a number of patients, in which an intra-aortic balloon pump is indicated on haemodynamic grounds, might not receive the device, mainly because of peripheral vessel disease and device unavailability.
The older age in the patients allocated to intra-aortic balloon pump therapy may underestimate the effect of this therapy; however, it is unlikely that this influenced outcome in a significant manner. This study was designed to include 266 patients. After inclusion of 90% of the patients, the study was stopped. However, it is unlikely that the primary or secondary end-point would be beneficial for intra-aortic balloon pump treated patients after inclusion of all 266 patients.
Conclusion
The systematic use of intra-aortic balloon pumping after angioplasty for acute myocardial infarction in high risk patients does not affect infarct size or left ventricular function and does not lead to a better clinical outcome when compared to elective use of the intra-aortic balloon pump.
The use of an intra-aortic balloon pump in patients after primary angioplasty should be reserved for patients with severe hemodynamic instability.
